Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
On April 11, 2025 in Switzerland on April 11, 2025 in Switzerland, on April 11, 2025, the Swiss company Novartis AG Novartis AG.
Sedat Suna | Getty Images | Gets the image
Swiss pharmaceutical firm Novartis On Tuesday, the sales were reported in the first quarter more than expected and raised their full years.
Net sales increased by 15% on a permanent currency to $ 13.2 billion, compared to $ 13.12 billion, estimated by LSEG analysts.
The main operating income increased by 27% to $ 5.07 billion.
Novartis also raised its full -fledged recommendations for 2025, predicted clean sales for high single numbers and basic operating income to increase the low double -digit.
The results come when the global pharmaceutical industry awaits breathing for the expected tariffs in the US after the Presidential Administration Donald Trump has launched an investigation into the sector earlier this month.
In the pharmaceutical Target pharmaceutical fees I would come to the “very closest future”.
The prospect of great responsibilities has fueled investments in the US by European pharmaceutical firms as they seek to maintain access to the profitable market and streamline domestic production.
Novartis announced earlier this month that a $ 23 billion to invest and expand 10 objects in the United States over the next five years, which, he said, will provide all key Novartis medicines for patients in the US.
CEO Novartis Vas Narasimhan, who has long been a bullish growth of his firm on the US market, said at the time What the tariffs were considered but not a driving factor in the firm’s decision.
This step was accompanied last week by the Swiss pharmaceutical firm Roche, which which promised to invest 50 billion In the US over the next five years and create more than 12,000 jobs.
Meanwhile, American firms Johnson and Johnson and Eli Lily also recently announced significant new investments in the US
This is a developing story. Please check the updates.
